Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma

C. H N Veenhof, M. E L van der Burg, M. Nooy, J. G. Aalders, S. Pecorelli, C. F. Oliveira, N. Rotmensz, J. B. Vermorken

Research output: Contribution to journalArticlepeer-review


The EORTC Gynaecological Cancer Cooperative Group conducted a phase II study of high dose oral megestrol acetate: 800 mg/day for 1 month followed by 400 mg/day as maintenance treatment, in heavily pretreated patients with ovarian cancer. Of 72 patients included in this study, 54 were fully evaluable for response and toxicity. The response rate was low with only 1 patient having a partial reponse, 9 patients with stable disease and 44 patients with progressive disease. The toxicity profile was low. However, 1 patient died after 2 months of treatment, and in 3 patients thrombo-embolic events occurred. Weight gain varied in 20 of the 61 patients from 0.5 to 16 kg. This study does not suggest that the overall 10% benefit from hormonal therapy for chemotherapy refractory ovarian cancer will improve by increasing the dose.

Original languageEnglish
Pages (from-to)697-698
Number of pages2
JournalEuropean Journal of Cancer
Issue number5
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma'. Together they form a unique fingerprint.

Cite this